227 related articles for article (PubMed ID: 17445089)
1. Perhexiline.
Ashrafian H; Horowitz JD; Frenneaux MP
Cardiovasc Drug Rev; 2007; 25(1):76-97. PubMed ID: 17445089
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent.
Cole PL; Beamer AD; McGowan N; Cantillon CO; Benfell K; Kelly RA; Hartley LH; Smith TW; Antman EM
Circulation; 1990 Apr; 81(4):1260-70. PubMed ID: 2180591
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses.
Willoughby SR; Chirkov YY; Kennedy JA; Murphy GA; Chirkova LP; Horowitz JD
Eur J Pharmacol; 1998 Sep; 356(2-3):207-13. PubMed ID: 9774251
[TBL] [Abstract][Full Text] [Related]
4. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart.
Kennedy JA; Kiosoglous AJ; Murphy GA; Pelle MA; Horowitz JD
J Cardiovasc Pharmacol; 2000 Dec; 36(6):794-801. PubMed ID: 11117381
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
[TBL] [Abstract][Full Text] [Related]
6. Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Inglis S; Stewart S
Eur J Cardiovasc Nurs; 2006 Jun; 5(2):175-84. PubMed ID: 16469541
[TBL] [Abstract][Full Text] [Related]
7. Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
Phuong H; Choi BY; Chong CR; Raman B; Horowitz JD
Ther Drug Monit; 2016 Feb; 38(1):73-8. PubMed ID: 26309031
[TBL] [Abstract][Full Text] [Related]
8. Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report.
Sheikh AR; Westley I; Sallustio B; Horowitz JD; Beltrame JF
Heart Lung Circ; 2014 Jun; 23(6):e149-51. PubMed ID: 24373912
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease.
Killalea SM; Krum H
Am J Cardiovasc Drugs; 2001; 1(3):193-204. PubMed ID: 14728034
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.
Kennedy JA; Unger SA; Horowitz JD
Biochem Pharmacol; 1996 Jul; 52(2):273-80. PubMed ID: 8694852
[TBL] [Abstract][Full Text] [Related]
11. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy.
Stewart S; Voss DW; Northey DL; Horowitz JD
Ther Drug Monit; 1996 Dec; 18(6):635-9. PubMed ID: 8946658
[TBL] [Abstract][Full Text] [Related]
12. Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state.
Jones TE; Morris RG; Horowitz JD
Br J Clin Pharmacol; 2004 Mar; 57(3):263-9. PubMed ID: 14998422
[TBL] [Abstract][Full Text] [Related]
13. Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium.
Unger SA; Kennedy JA; McFadden-Lewis K; Minerds K; Murphy GA; Horowitz JD
J Cardiovasc Pharmacol; 2005 Dec; 46(6):849-55. PubMed ID: 16306812
[TBL] [Abstract][Full Text] [Related]
14. Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.
Chong CR; Sallustio B; Horowitz JD
Cardiovasc Drugs Ther; 2016 Aug; 30(4):399-405. PubMed ID: 27106834
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic mechanisms of action of perhexiline in heart failure.
George CH; Mitchell AN; Preece R; Bannister ML; Yousef Z
Expert Opin Ther Pat; 2016 Sep; 26(9):1049-59. PubMed ID: 27455171
[TBL] [Abstract][Full Text] [Related]
16. Metabolic modulation: a new therapeutic target in treatment of heart failure.
Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
[TBL] [Abstract][Full Text] [Related]
17. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Rupp H; Zarain-Herzberg A; Maisch B
Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
[TBL] [Abstract][Full Text] [Related]
18. Effect of Ca2+-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, on platelet aggregation in vitro.
Ono H; Kimura M
Arzneimittelforschung; 1981; 31(7):1131-4. PubMed ID: 7196762
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats.
Licari G; Somogyi AA; Milne RW; Sallustio BC
Xenobiotica; 2015 Jan; 45(1):3-9. PubMed ID: 25050791
[TBL] [Abstract][Full Text] [Related]
20. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart.
Kennedy JA; Horowitz JD
Cardiovasc Drugs Ther; 1998 Sep; 12(4):359-63. PubMed ID: 9825181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
